Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 10OTHER 6NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Vincristine 17Cyclophosphamide 17Cytarabine 16Methotrexate 14Doxorubicin 14Prednisone 11Etoposide 11Radiotherapy 10merphos 9Rituximab 8Dexamethasone 8pegaspargase 7Leucovorin 7Filgrastim 7Calcium Dobesilate 7Methylprednisolone 6Daunorubicin 6dexamethasone acetate 5dexamethasone 21-phosphate 5calaspargase pegol 5azathiopurine 5auricularum 5Thioguanine 5Mercaptopurine 5Hydrocortisone 5Granulocyte Colony-Stimulating Factor 5Asparaginase 5prednylidene 4deltacortene 4Specimen Handling 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Burkitt Lymphoma × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡